Nephro Trial Files: Eculizumab vs. Placebo for STEC-HUS, Taurolidine/Heparin Lock Solution for Reducing CRBSI in Hemodialysis, and Glutamine for AKI After Cardiac Surgery
Nephro Trial Files: Eculizumab vs. Placebo for STEC-HUS, Taurolidine/Heparin Lock Solution for Reducing CRBSI in Hemodialysis, and Glutamine for AKI After Cardiac Surgery
nephrotrialfiles.substack.com
Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin–Related Hemolytic and Uremic Syndrome Garnier A et al. JASN (September 2023) Bottom Line: This Phase 3 randomized, placebo-controlled trial included 100 pediatric patients with Shiga toxin-related hemolytic uremic syndrome (STEC-HUS). Patients were randomly assigned in a 1:1 ratio to receive either eculizumab or placebo during 4 weeks, with follow-up lasting for 1 year. The primary end point was renal replacement therapy (RRT) duration <48 hours after randomization. Results showed no significant difference between the two groups (48% in the placebo versus 38% in the eculizumab group; P = 0.31). However, the proportion of patients experiencing renal sequelae at 1 year was lower in the eculizumab group than in the placebo group (43.48% and 64.44%, respectively, P = 0.04). No safety concerns were reported.
Nephro Trial Files: Eculizumab vs. Placebo for STEC-HUS, Taurolidine/Heparin Lock Solution for Reducing CRBSI in Hemodialysis, and Glutamine for AKI After Cardiac Surgery
Nephro Trial Files: Eculizumab vs. Placebo…
Nephro Trial Files: Eculizumab vs. Placebo for STEC-HUS, Taurolidine/Heparin Lock Solution for Reducing CRBSI in Hemodialysis, and Glutamine for AKI After Cardiac Surgery
Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin–Related Hemolytic and Uremic Syndrome Garnier A et al. JASN (September 2023) Bottom Line: This Phase 3 randomized, placebo-controlled trial included 100 pediatric patients with Shiga toxin-related hemolytic uremic syndrome (STEC-HUS). Patients were randomly assigned in a 1:1 ratio to receive either eculizumab or placebo during 4 weeks, with follow-up lasting for 1 year. The primary end point was renal replacement therapy (RRT) duration <48 hours after randomization. Results showed no significant difference between the two groups (48% in the placebo versus 38% in the eculizumab group; P = 0.31). However, the proportion of patients experiencing renal sequelae at 1 year was lower in the eculizumab group than in the placebo group (43.48% and 64.44%, respectively, P = 0.04). No safety concerns were reported.